We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should Value Investors Buy Vir Biotechnology (VIR) Stock?
Read MoreHide Full Article
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.
In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.
Vir Biotechnology (VIR - Free Report) is a stock many investors are watching right now. VIR is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A.
Investors should also recognize that VIR has a P/B ratio of 1.67. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. This company's current P/B looks solid when compared to its industry's average P/B of 3.50. Over the past 12 months, VIR's P/B has been as high as 8.05 and as low as 1.19, with a median of 1.75.
Finally, investors should note that VIR has a P/CF ratio of 3.18. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. VIR's current P/CF looks attractive when compared to its industry's average P/CF of 8.48. Over the past 52 weeks, VIR's P/CF has been as high as 10.49 and as low as -74.52, with a median of 2.83.
These figures are just a handful of the metrics value investors tend to look at, but they help show that Vir Biotechnology is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, VIR feels like a great value stock at the moment.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Should Value Investors Buy Vir Biotechnology (VIR) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.
In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.
Vir Biotechnology (VIR - Free Report) is a stock many investors are watching right now. VIR is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A.
Investors should also recognize that VIR has a P/B ratio of 1.67. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. This company's current P/B looks solid when compared to its industry's average P/B of 3.50. Over the past 12 months, VIR's P/B has been as high as 8.05 and as low as 1.19, with a median of 1.75.
Finally, investors should note that VIR has a P/CF ratio of 3.18. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. VIR's current P/CF looks attractive when compared to its industry's average P/CF of 8.48. Over the past 52 weeks, VIR's P/CF has been as high as 10.49 and as low as -74.52, with a median of 2.83.
These figures are just a handful of the metrics value investors tend to look at, but they help show that Vir Biotechnology is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, VIR feels like a great value stock at the moment.